762 related articles for article (PubMed ID: 34730399)
1. Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors.
Khatun M; Kumar K; Baidya A; Mondal RK; Baszczyňski O; Kalčic F; Banerjee S; Dhali GK; Das K; Chowdhury A; Janeba Z; Chakrabarti S; Datta S
J Virol; 2022 Jan; 96(2):e0180021. PubMed ID: 34730399
[TBL] [Abstract][Full Text] [Related]
2. Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.
Shao J; Liu Y; Liu LM; Chen R; Zhao L; Zhou Y; Li L; Li X; Li J; Xu D
J Infect Dev Ctries; 2021 Jan; 15(1):131-140. PubMed ID: 33571155
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures.
Zhang Q; Han T; Nie CY; Ha FS; Liu L; Liu H
J Med Virol; 2015 Jun; 87(6):1013-21. PubMed ID: 25716029
[TBL] [Abstract][Full Text] [Related]
6. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial.
Yim HJ; Kim IH; Suh SJ; Jung YK; Kim JH; Seo YS; Yeon JE; Kim CW; Kwon SY; Park SH; Lee MS; Um SH; Byun KS
J Viral Hepat; 2018 Nov; 25(11):1321-1330. PubMed ID: 29772084
[TBL] [Abstract][Full Text] [Related]
7. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study.
Yuan G; Hu C; Zhou Y; Liu J; Huang H; Li Y; Yang D; Zhou F; Zhang YY; Zhou Y
Br J Clin Pharmacol; 2017 Oct; 83(10):2259-2265. PubMed ID: 28511283
[TBL] [Abstract][Full Text] [Related]
8. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
[TBL] [Abstract][Full Text] [Related]
9. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
[TBL] [Abstract][Full Text] [Related]
12. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy.
Shirvani-Dastgerdi E; Winer BY; Celià-Terrassa T; Kang Y; Tabernero D; Yagmur E; Rodríguez-Frías F; Gregori J; Luedde T; Trautwein C; Ploss A; Tacke F
J Hepatol; 2017 Aug; 67(2):246-254. PubMed ID: 28392234
[TBL] [Abstract][Full Text] [Related]
13. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes.
Lee AR; Cho JY; Kim JC; Dezhbord M; Choo SY; Ahn CH; Kim NY; Shin JJ; Park S; Park ES; Won J; Kim DS; Lee JH; Kim KH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562603
[TBL] [Abstract][Full Text] [Related]
14. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains.
Lee YB; Lee JH; Lee DH; Cho H; Ahn H; Choi WM; Cho YY; Lee M; Yoo JJ; Cho Y; Cho EJ; Yu SJ; Kim YJ; Yoon JH; Kim CY; Lee HS
Antimicrob Agents Chemother; 2014 Nov; 58(11):6710-6. PubMed ID: 25155601
[TBL] [Abstract][Full Text] [Related]
16. Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.
Boglione L; De Benedetto I; Lupia T; Cusato J; Cariti G; Di Perri G
Arch Virol; 2021 Apr; 166(4):1125-1131. PubMed ID: 33580380
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.
Lim YS; Yoo BC; Byun KS; Kwon SY; Kim YJ; An J; Lee HC; Lee YS
Gut; 2016 Jun; 65(6):1042-51. PubMed ID: 25800784
[TBL] [Abstract][Full Text] [Related]
19. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
